Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166855 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9ANPC1MAPTL3MBTL1 | |
| SCHEMBL2507068 | 0.73 | HPGD (0.36) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL734040 | 0.71 | CNR2 (0.39) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL735313 | 0.70 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL25929714 | 0.69 | SMN1; SMN2 (0.38) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25933391 | 0.69 | CNR2 (0.36) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25933390 | 0.69 | CNR2 (0.36) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15349095 | 0.69 | CNR2 (0.36) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15349100 | 0.69 | CNR2 (0.36) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5376501 | 0.68 | SMN1; SMN2 (0.40) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3817817-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| CN-112584899-A | NLRP modulators | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267276-A1 | NLRP MODULATORS | NLRP1, NRP1, NR4A3 | SMN1; SMN2 3669/4885NOS1 2305/4885SLC6A2 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.